Resources

eXmoor Pharma and Evox Therapeutics announce the successful completion of a technology transfer programme for Evox’s exosome-enabled gene editing technology.

Theolytics has relocated to ARC Oxford, taking 5,500 SQF at the growing innovation campus.

Pioneer Group, a specialist life science infrastructure and venture building business, and Firoka, a hospitality and real estate group, have secured unanimous resolution to grant planning permission for the transformation of Ozone Leisure Park in Oxford.

The British Business Bank has invested in Draig Therapeutics as part of its $65 million Series B financing round.

The Milner Therapeutics Institute has joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.

Milner Institute convenes science, industry, investors and charity funders for Pitch Day and Symposium

Some of the UK's most promising student food innovators gathered at Colworth Science Park this month for the 2026 Ecotrophelia UK final, where seven university teams presented eco-innovative food concepts to a panel of industry judges.

Poolbeg Pharma today announces that the first patient has been dosed in the POLB 001 TOPICAL clinical trial.

Major VectorBee update reflects VectorBuilder’s continued investment in free, researcher-first tools for genetic engineering and vector design.

Autolomous and Cellular Origins today announce end-to-end integration of their respective platforms, bringing full automation and digitisation to the entire cell therapy manufacturing process.

Lucideon is expanding its global support for medical device innovation with the launch of a new biocompatibility laboratory in Greenville, South Carolina. Working alongside its UK cell biology laboratory, the new facility will provide a comprehensive range of biocompatibility testing and materials characterisation services from a single source, helping manufacturers accelerate product development, meet regulatory requirements, and bring safer medical devices to market with greater confidence. The investment strengthens Lucideon’s ability to support the next generation of medical technologies, from advanced implants and biomaterials to wearable devices, while helping protect patient safety worldwide. Read the full story to discover how Lucideon is creating a global biocompatibility and materials performance solution for medical device innovators.

Boyds, a leading global drug development consultancy, is pleased to announce the appointment of Laurence Skillern as Chief Medical Officer.

EnteroBiotix announced that the first patient has been dosed in RISE, its Phase 2b clinical trial evaluating EBX-102-02 in moderate-to-severe irritable bowel syndrome with constipation (IBS-C).

Coulter Partners successfully led a search for Salvia BioElectronics B.V. to place Jill Schiaparelli as Chair of its Board of Directors.

Myricx Bio reached agreement to be acquired by Novartis for up to $1.5 billion.

Astex has entered into an exclusive, worldwide research collaboration and license agreement with Genentech.

Brandon Capital announced the successful exit of its portfolio company Myricx Bio.

Craig Marshall, $1.5B OrganOx exit CEO, joins Oxford Medical Products board

Innovation Orbit 2026 is FI Group by EPSA’s international guide to grants, R&D tax credits and public incentives for businesses planning R&D, CAPEX, digital transformation or decarbonisation projects.

KQ Labs, a leading accelerator that has helped early-stage life sciences innovators raise over £230 million, is now accepting applications for its ninth programme